(Q46079516)

19 December 2017

title

Atorvastatin effect on the distribution of high-density lipoprotein subfractions and human paraoxonase activity (English)

1 reference

19 December 2017

author

Mariann Harangi

1

1 reference

19 December 2017

author name string

Hossein Z Mirdamadi

2

1 reference

19 December 2017

Ildikó Seres

3

1 reference

19 December 2017

Ferenc Sztanek

4

1 reference

19 December 2017

Miklós Molnár

5

1 reference

19 December 2017

Andrea Kassai

6

1 reference

19 December 2017

Zoltán Derdák

7

1 reference

19 December 2017

László Illyés

8

1 reference

19 December 2017

György Paragh

9

1 reference

19 December 2017

publication date

14 February 2009

1 reference

19 December 2017

published in

Translational Research

1 reference

19 December 2017

volume

153

1 reference

19 December 2017

issue

4

1 reference

19 December 2017

page(s)

190-198

1 reference

19 December 2017

Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.01.007

Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.01.007

Molecular basis of differences among statins and a comparison with antioxidant vitamins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.01.007

Laboratory assessment of HDL heterogeneity and function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.01.007

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.01.007

Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.01.007

Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.01.007

Detailed molecular model of apolipoprotein A-I on the surface of high-density lipoproteins and its functional implications.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.01.007

Apolipoprotein J is associated with paraoxonase in human plasma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.01.007

Studies on human serum paraoxonase/arylesterase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.01.007

Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.01.007

Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.01.007

Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.01.007

Subpopulations of apolipoprotein A-I in human high-density lipoproteins. Their metabolic properties and response to drug therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.01.007

HDL subfraction distribution of paraoxonase-1 and its relevance to enzyme activity and resistance to oxidative stress.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.01.007

Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.01.007

Effects of atorvastatin on the HDL subpopulation profile of coronary heart disease patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.01.007

Pitavastatin decreases plasma prebeta1-HDL concentration and might promote its disappearance rate in hypercholesterolemic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.01.007

Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.01.007

Effects of maximal doses of atorvastatin versus rosuvastatin on small dense low-density lipoprotein cholesterol levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.01.007

Atorvastatin reduces remnant lipoproteins and small, dense low-density lipoproteins regardless of the baseline lipid pattern

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.01.007

The effect of atorvastatin therapy on lecithin:cholesterol acyltransferase, cholesteryl ester transfer protein and the antioxidant paraoxonase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.01.007

The serum paraoxonase activity in patients with chronic renal failure and hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.01.007

Characterization of human high-density lipoproteins by gradient gel electrophoresis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.01.007

Effect of Diabetes on Lipoprotein Size

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.01.007

Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.01.007

A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.01.007

The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: results of NHLBI Type II Coronary Intervention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.01.007

LDL and HDL subclasses and their relationship with Framingham risk score in middle-aged Serbian population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.01.007

Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.01.007

Efficacy and safety of simvastatin for high-risk hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.01.007

Inhibition of cholesteryl ester transfer protein increases serum apolipoprotein (apo) A-I levels by increasing the synthesis of apo A-I in rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.01.007

Opposite effects of cholesteryl ester transfer protein and phospholipid transfer protein on the size distribution of plasma high density lipoproteins. Physiological relevance in alcoholic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.01.007

Contribution of cholesteryl ester transfer protein and lecithin:cholesterol acyltransferase to HDL size distribution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.01.007

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.01.007

The effect of statin therapy on plasma high-density lipoprotein cholesterol levels is modified by paraoxonase-1 in patients with familial hypercholesterolaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.01.007

Distribution spectrum of paraoxonase activity in HDL fractions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.01.007

Effect of short term treatment with simvastatin and atorvastatin on lipids and paraoxonase activity in patients with hyperlipoproteinaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.01.007

Atorvastatin effect on high-density lipoprotein-associated paraoxonase activity and oxidative DNA damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.01.007

Association of oxidative stress and PON1 with LDL and HDL particle size in middle-aged subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.01.007

10.1016/J.TRSL.2009.01.007

7 January 2021

Identifiers

DOI

1 reference

19 December 2017

1 reference

19 December 2017